{
  "response": {
    "status": 200
  },
  "symbol": {
    "id": 6183,
    "symbol": "LLY",
    "title": "Eli Lilly & Co.",
    "aliases": [],
    "is_following": false,
    "watchlist_count": 7403
  },
  "cursor": {
    "more": true,
    "since": 262773848,
    "max": 262675101
  },
  "messages": [
    {
      "id": 262773848,
      "body": "$LLY presents positive primary outcome data from monarchE that builds on previous definitive analysis for Verzenio\u00ae https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20201209090541LLY",
      "created_at": "2020-12-09T16:06:46Z",
      "user": {
        "id": 8115,
        "username": "briefingcom",
        "name": "Briefingcom",
        "avatar_url": "https://avatars.stocktwits.com/production/8115/thumb-1340802633.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/8115/thumb-1340802633.png",
        "join_date": "2010-01-25",
        "official": true,
        "identity": "Official",
        "classification": [
          "official"
        ],
        "followers": 85729,
        "following": 821,
        "ideas": 83095,
        "watchlist_stocks_count": 8,
        "like_count": 68,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2269,
        "title": "StockTwits Web",
        "url": "https://stocktwits.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7406
        }
      ],
      "links": [
        {
          "title": "Briefing.com",
          "url": "https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20201209090541LLY",
          "shortened_url": "https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20201209090541LLY",
          "shortened_expanded_url": "briefing.com/in-depth-analy...",
          "description": "LLY: Eli Lilly presents positive primary outcome data from monarchE that builds on previous definitive analysis for Verzenio\u00ae (149.30) Co announced additional data from a pre-planned primary outcome analysis from the Phase 3 monarchE trial that showed Verzenio\u00ae (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) decreased the risk of breast cancer recurrence by 28.7 percent compared to standard adjuvant ET alone for people with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (HR: 0.713; 95% CI: 0.583, 0.871; p = 0.0009).",
          "image": null,
          "created_at": "2020-12-09T16:06:47Z",
          "video_url": null,
          "source": {
            "name": "Briefing",
            "website": "https://www.briefing.com"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262766486,
      "body": "2020-12-09 15:52:22+00:00 $CTXS, $ETSY, $FWRD, $LLY, $MTZ, $TMSNY    Intra-day Move",
      "created_at": "2020-12-09T15:52:22Z",
      "user": {
        "id": 1511377,
        "username": "YuMiStocks_Trade",
        "name": "YuMIStocksTrade.com",
        "avatar_url": "https://avatars.stocktwits.com/production/1511377/thumb-1596895665.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/1511377/thumb-1596895665.png",
        "join_date": "2018-06-04",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 404,
        "following": 1,
        "ideas": 9010,
        "watchlist_stocks_count": 34,
        "like_count": 602,
        "plus_tier": "month",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 5846,
        "title": "ConfluxBot",
        "url": "https://app.confluxbot.com"
      },
      "symbols": [
        {
          "id": 1506,
          "symbol": "CTXS",
          "title": "Citrix Systems, Inc.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 2443
        },
        {
          "id": 1968,
          "symbol": "FWRD",
          "title": "Forward Air Corp.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 81
        },
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7406
        },
        {
          "id": 6402,
          "symbol": "MTZ",
          "title": "MasTec, Inc.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 1166
        },
        {
          "id": 7996,
          "symbol": "ETSY",
          "title": "Etsy",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 22865
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262761136,
      "body": "$JPM $LLY Lilly Jumps After Results From Next Generation Diabetes Drug \n\nhttps://newsfilter.io/a/52c971490f01aee1e19bd7a047230869",
      "created_at": "2020-12-09T15:42:03Z",
      "user": {
        "id": 2762379,
        "username": "Newsfilter",
        "name": "@newsfilterio",
        "avatar_url": "https://avatars.stocktwits.com/production/2762379/thumb-1570180226.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/2762379/thumb-1570180226.png",
        "join_date": "2019-09-01",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 8096,
        "following": 16,
        "ideas": 666410,
        "watchlist_stocks_count": 1,
        "like_count": 531,
        "plus_tier": "month",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2269,
        "title": "StockTwits Web",
        "url": "https://stocktwits.com"
      },
      "symbols": [
        {
          "id": 6020,
          "symbol": "JPM",
          "title": "JPMorgan Chase & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 59458
        },
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7403
        }
      ],
      "links": [
        {
          "title": "Lilly Jumps After Results From Next Generation Diabetes Drug",
          "url": "https://newsfilter.io/a/52c971490f01aee1e19bd7a047230869",
          "shortened_url": "https://newsfilter.io/a/52c971490f01aee1e19bd7a047230869",
          "shortened_expanded_url": "newsfilter.io/a/52c971490f0...",
          "description": "Lilly Jumps After Results From Next Generation Diabetes Drug: Please sign in to read this article.",
          "image": null,
          "created_at": "2020-12-09T15:42:04Z",
          "video_url": null,
          "source": {
            "name": "Newsfilter",
            "website": "https://newsfilter.io"
          }
        }
      ],
      "likes": {
        "total": 1,
        "user_ids": [
          2142801
        ]
      },
      "mentioned_users": [],
      "entities": {
        "chart": {
          "thumb": "https://charts.stocktwits.com/production/small_262761136.jpg",
          "large": "https://charts.stocktwits.com/production/large_262761136.jpg",
          "original": "https://charts.stocktwits.com/production/original_262761136.jpg",
          "url": "https://charts.stocktwits.com/production/original_262761136.jpg"
        },
        "sentiment": null
      }
    },
    {
      "id": 262761045,
      "body": "$LLY Lilly\u2019s verzenio data shows decrease in breast cancer recurrence \n\nhttps://newsfilter.io/a/1af6ed82fd345eba2d7c61b87bd5d2f1",
      "created_at": "2020-12-09T15:41:54Z",
      "user": {
        "id": 2762379,
        "username": "Newsfilter",
        "name": "@newsfilterio",
        "avatar_url": "https://avatars.stocktwits.com/production/2762379/thumb-1570180226.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/2762379/thumb-1570180226.png",
        "join_date": "2019-09-01",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 8095,
        "following": 16,
        "ideas": 666255,
        "watchlist_stocks_count": 1,
        "like_count": 531,
        "plus_tier": "month",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2269,
        "title": "StockTwits Web",
        "url": "https://stocktwits.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7406
        }
      ],
      "links": [
        {
          "title": "Lilly's verzenio data shows decrease in breast cancer recurrence",
          "url": "https://newsfilter.io/a/1af6ed82fd345eba2d7c61b87bd5d2f1",
          "shortened_url": "https://newsfilter.io/a/1af6ed82fd345eba2d7c61b87bd5d2f1",
          "shortened_expanded_url": "newsfilter.io/a/1af6ed82fd3...",
          "description": "Lilly's verzenio data shows decrease in breast cancer recurrence: Eli Lilly has reported additional data from a pre-planned primary outcome analysis from Phase 3 monarchE trial evaluating Verzenio in ..",
          "image": null,
          "created_at": "2020-12-09T15:41:54Z",
          "video_url": null,
          "source": {
            "name": "Newsfilter",
            "website": "https://newsfilter.io"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262759169,
      "body": "$LLY Stock is probably up today because of Peter Thiel IPO, AbCellera (ABCL) going public tomorrow.  LLY heavily involved with this company.",
      "created_at": "2020-12-09T15:38:24Z",
      "user": {
        "id": 1044892,
        "username": "stklover",
        "name": "George Schembry",
        "avatar_url": "https://avatars.stocktwits.com/production/1044892/thumb-1558038188.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/1044892/thumb-1558038188.png",
        "join_date": "2017-04-27",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 49,
        "following": 130,
        "ideas": 3906,
        "watchlist_stocks_count": 155,
        "like_count": 3557,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 1149,
        "title": "StockTwits for iOS",
        "url": "http://www.stocktwits.com/mobile"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7403
        }
      ],
      "likes": {
        "total": 1,
        "user_ids": [
          2142801
        ]
      },
      "mentioned_users": [],
      "entities": {
        "sentiment": {
          "basic": "Bullish"
        }
      }
    },
    {
      "id": 262758103,
      "body": "$LLY  Have fun buying my 113+ shares this 3 month roller coaster with Lilly has come to an end....mostly \ud83d\ude1c",
      "created_at": "2020-12-09T15:36:31Z",
      "user": {
        "id": 4156323,
        "username": "IndyToPuertoRico",
        "name": "Ryan S",
        "avatar_url": "http://avatars.stocktwits.com/images/default_avatar_thumb.jpg",
        "avatar_url_ssl": "https://s3.amazonaws.com/st-avatars/images/default_avatar_thumb.jpg",
        "join_date": "2020-10-07",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 0,
        "following": 0,
        "ideas": 15,
        "watchlist_stocks_count": 18,
        "like_count": 7,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 1149,
        "title": "StockTwits for iOS",
        "url": "http://www.stocktwits.com/mobile"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7406
        }
      ],
      "conversation": {
        "parent_message_id": 262758103,
        "in_reply_to_message_id": null,
        "parent": true,
        "replies": 1
      },
      "likes": {
        "total": 1,
        "user_ids": [
          1821472
        ]
      },
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262756862,
      "body": "$LLY Eli Lilly Sees Positive Data From Late-Stage Trial of Diabetes Treatment Tirzepatide\n\nhttps://www.thestreet.com/investing",
      "created_at": "2020-12-09T15:34:16Z",
      "user": {
        "id": 962572,
        "username": "topstockalerts",
        "name": "Top Stock Alerts",
        "avatar_url": "https://avatars.stocktwits.com/production/962572/thumb-1506783043.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/962572/thumb-1506783043.png",
        "join_date": "2017-02-19",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 58234,
        "following": 51,
        "ideas": 122873,
        "watchlist_stocks_count": 10,
        "like_count": 2235,
        "plus_tier": "life",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2095,
        "title": "StockTwits For Android ",
        "url": "http://www.stocktwits.com/mobile"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7406
        }
      ],
      "links": [
        {
          "title": "INVESTING",
          "url": "https://www.thestreet.com/investing",
          "shortened_url": "https://www.thestreet.com/investing",
          "shortened_expanded_url": "thestreet.com/investing",
          "description": "\u00a9 2020 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.",
          "image": "https://www.thestreet.com/.image/ar_16:9%2Cc_fill%2Ccs_srgb%2Cfl_progressive%2Cg_faces:center%2Cq_auto:good%2Cw_620/MTY4NjM1NDk0ODY2MDM2MzU5/winter-storm-hercules-to-hurt-sales-at-vera-bradley-tjx.jpg",
          "created_at": "2020-12-09T15:34:17Z",
          "video_url": null,
          "source": {
            "name": "TheStreet",
            "website": "https://www.thestreet.com"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262752070,
      "body": "$LLY  - are we going to see 52 week high today?",
      "created_at": "2020-12-09T15:25:51Z",
      "user": {
        "id": 3137539,
        "username": "Options_Newbie",
        "name": "Devang Dave",
        "avatar_url": "http://avatars.stocktwits.com/images/default_avatar_thumb.jpg",
        "avatar_url_ssl": "https://s3.amazonaws.com/st-avatars/images/default_avatar_thumb.jpg",
        "join_date": "2020-02-29",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 0,
        "following": 2,
        "ideas": 11,
        "watchlist_stocks_count": 18,
        "like_count": 12,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2269,
        "title": "StockTwits Web",
        "url": "https://stocktwits.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7406
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262745572,
      "body": "$LLY lol",
      "created_at": "2020-12-09T15:14:39Z",
      "user": {
        "id": 1030807,
        "username": "starkseason",
        "name": "shiny",
        "avatar_url": "https://avatars.stocktwits.com/production/1030807/thumb-1546551373.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/1030807/thumb-1546551373.png",
        "join_date": "2017-04-17",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 103,
        "following": 244,
        "ideas": 11912,
        "watchlist_stocks_count": 224,
        "like_count": 1257,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2095,
        "title": "StockTwits For Android ",
        "url": "http://www.stocktwits.com/mobile"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7407
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262744773,
      "body": "2020-12-09 15:13:17+00:00 $CCMP, $LLY, $RL, $SNEX, $UGLDF, $ZG    Intra-day Move",
      "created_at": "2020-12-09T15:13:18Z",
      "user": {
        "id": 1511377,
        "username": "YuMiStocks_Trade",
        "name": "YuMIStocksTrade.com",
        "avatar_url": "https://avatars.stocktwits.com/production/1511377/thumb-1596895665.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/1511377/thumb-1596895665.png",
        "join_date": "2018-06-04",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 404,
        "following": 1,
        "ideas": 9010,
        "watchlist_stocks_count": 34,
        "like_count": 602,
        "plus_tier": "month",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 5846,
        "title": "ConfluxBot",
        "url": "https://app.confluxbot.com"
      },
      "symbols": [
        {
          "id": 1235,
          "symbol": "CCMP",
          "title": "Cabot Microelectronics Corp.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 195
        },
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7407
        },
        {
          "id": 7039,
          "symbol": "RL",
          "title": "Polo Ralph Lauren Corp.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 2423
        },
        {
          "id": 9496,
          "symbol": "SNEX",
          "title": "Stonex Group Inc",
          "aliases": [
            "IAAC"
          ],
          "is_following": false,
          "watchlist_count": 373
        },
        {
          "id": 12839,
          "symbol": "ZG",
          "title": "Zillow Class A",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 2868
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262712612,
      "body": "$LLY [15s. delayed]: Issued Press Release on December 09, 09:00:00: Lilly Presents Positive Primary Outcome Data from monarchE that Builds https://s.flashalert.me/3hPhK4",
      "created_at": "2020-12-09T14:13:22Z",
      "user": {
        "id": 595702,
        "username": "fla",
        "name": "FlashAlert_me",
        "avatar_url": "https://avatars.stocktwits.com/production/595702/thumb-1550769466.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/595702/thumb-1550769466.png",
        "join_date": "2015-09-09",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 2843,
        "following": 60,
        "ideas": 774855,
        "watchlist_stocks_count": 0,
        "like_count": 4,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 4622,
        "title": "FlashAlert",
        "url": "https://flashalert.me/"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7407
        }
      ],
      "links": [
        {
          "title": "Flash Alert",
          "url": "https://s.flashalert.me/3hPhK4",
          "shortened_url": "https://s.flashalert.me/3hPhK4",
          "shortened_expanded_url": "prnewswire.com:443/news-rel...",
          "description": "Real-time alerts about equities, ETFs, cryptocurrencies and more sent to any device",
          "image": null,
          "created_at": "2020-12-09T14:13:22Z",
          "video_url": null,
          "source": {
            "name": "Flashalert",
            "website": "https://flashalert.me"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262712423,
      "body": "$LLY | Eli Lilly Sees Positive Data From Late-Stage Trial of Diabetes Treatment Tirzepatide https://finance.yahoo.com/m/f20376ad-b1e9-39b1-8ddb-efea08d3c95a/eli-lilly-sees-positive-data.html",
      "created_at": "2020-12-09T14:12:53Z",
      "user": {
        "id": 130351,
        "username": "LiveSquawk",
        "name": "Live Squawk",
        "avatar_url": "https://avatars.stocktwits.com/production/130351/thumb-1572019929.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/130351/thumb-1572019929.png",
        "join_date": "2012-01-18",
        "official": true,
        "identity": "Official",
        "classification": [
          "suggested",
          "official"
        ],
        "followers": 229453,
        "following": 90,
        "ideas": 146767,
        "watchlist_stocks_count": 22,
        "like_count": 13,
        "plus_tier": "month",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2269,
        "title": "StockTwits Web",
        "url": "https://stocktwits.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7407
        }
      ],
      "links": [
        {
          "title": "Eli Lilly Sees Positive Data From Late-Stage Trial of Diabetes Treatment Tirzepatide",
          "url": "https://finance.yahoo.com/m/f20376ad-b1e9-39b1-8ddb-efea08d3c95a/eli-lilly-sees-positive-data.html",
          "shortened_url": "https://finance.yahoo.com/m/f20376ad-b1e9-39b1-8ddb-efea08d3c95a/eli-lilly-sees-positive-data.html",
          "shortened_expanded_url": "finance.yahoo.com/m/f20376a...",
          "description": "Eli Lilly said its developing type-2 diabetes treatment, tirzepatide, significantly reduced A1C and bodyweight levels during late-stage trials.",
          "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
          "created_at": "2020-12-09T14:12:54Z",
          "video_url": null,
          "source": {
            "name": "Yahoo",
            "website": "https://finance.yahoo.com"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262711058,
      "body": "$LLY NEW ARTICLE : Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio\u00ae https://www.stck.pro/news/LLY/9531246",
      "created_at": "2020-12-09T14:09:38Z",
      "user": {
        "id": 1555408,
        "username": "STCKPRO",
        "name": "STCK.PRO",
        "avatar_url": "https://avatars.stocktwits.com/production/1555408/thumb-1576077822.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/1555408/thumb-1576077822.png",
        "join_date": "2018-07-24",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 4863,
        "following": 2,
        "ideas": 298720,
        "watchlist_stocks_count": 18,
        "like_count": 52,
        "plus_tier": "month",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 5011,
        "title": "STCK.PRO",
        "url": "https://dashboard.stck.pro"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7407
        }
      ],
      "links": [
        {
          "title": "ELI LILLY AND COMPANY (LLY) News - STCK.PRO",
          "url": "https://www.stck.pro/news/LLY/9531246",
          "shortened_url": "https://www.stck.pro/news/LLY/9531246",
          "shortened_expanded_url": "stck.pro/news/LLY",
          "description": "Never miss an important article again, stay on top of your investments and become a better investor today! Get your moat on and sync your watchlist with Stocktwits and get all the latest news for your symbols. Sync with Stocktwits",
          "image": "https://www.stck.pro/img/noog.png",
          "created_at": "2020-12-09T14:09:40Z",
          "video_url": null,
          "source": {
            "name": "STCK.PRO",
            "website": "https://www.stck.pro"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "chart": {
          "thumb": "https://charts.stocktwits.com/production/small_262711058.jpg",
          "large": "https://charts.stocktwits.com/production/large_262711058.jpg",
          "original": "https://charts.stocktwits.com/production/original_262711058.jpg",
          "url": "https://charts.stocktwits.com/production/original_262711058.jpg"
        },
        "sentiment": null
      }
    },
    {
      "id": 262708384,
      "body": "$LLY -   Today announced additional data from a pre-planned primary outcome analysis from the Phase 3 monarchE trial that showed Verzenio\u00ae (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) decreased the risk of breast cancer recurrence by 28.7 percent compared to standard adjuvant ET alone for people with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (HR: 0.713; 95% CI: 0.583, 0.871; p = 0.0009). This statistically significant improvement corresponds to a three percent difference in the two-year rate of invasive disease-free survival (IDFS) between arms (92.3 percent in the Verzenio arm and 89.3 percent in the control arm).",
      "created_at": "2020-12-09T14:02:35Z",
      "user": {
        "id": 1665157,
        "username": "sbiswas",
        "name": "Soumyajyoti Biswas",
        "avatar_url": "https://avatars.stocktwits.com/production/1665157/thumb-1598680399.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/1665157/thumb-1598680399.png",
        "join_date": "2018-10-17",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 362,
        "following": 58,
        "ideas": 4709,
        "watchlist_stocks_count": 22,
        "like_count": 74,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2269,
        "title": "StockTwits Web",
        "url": "https://stocktwits.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7407
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262708178,
      "body": "$LLY ($149.3) Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive A https://marketbit.pro/r/lmM9znwh",
      "created_at": "2020-12-09T14:01:59Z",
      "user": {
        "id": 1442579,
        "username": "StockMeinfo",
        "name": "StockMe.info",
        "avatar_url": "https://avatars.stocktwits.com/production/1442579/thumb-1605608355.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/1442579/thumb-1605608355.png",
        "join_date": "2018-03-13",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 155,
        "following": 6,
        "ideas": 4587,
        "watchlist_stocks_count": 13,
        "like_count": 2,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2269,
        "title": "StockTwits Web",
        "url": "https://stocktwits.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7407
        }
      ],
      "links": [
        {
          "title": "Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio",
          "url": "https://marketbit.pro/r/lmM9znwh",
          "shortened_url": "https://marketbit.pro/r/lmM9znwh",
          "shortened_expanded_url": "marketbit.pro/news/2020/12/...",
          "description": "INDIANAPOLIS, Dec. 9, 2020 INDIANAPOLIS, Dec. 9, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced additional data from a pre-planned primary outcome analysis from the Phase 3 monarchE trial that showed Verzenio \u00ae (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) decreased the risk of breast cancer recurrence by 28.7 percent compared to standard adjuvant ET alone for people with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (HR: 0.713; 95% CI: 0.583, 0.871; p = 0.0009).",
          "image": "https://www.marketbit.pro/gfx/mbSquareMeta.jpeg?img=true",
          "created_at": "2020-12-09T14:02:01Z",
          "video_url": null,
          "source": {
            "name": "Marketbit",
            "website": "https://www.marketbit.pro"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262707897,
      "body": "$LLY Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio\u00ae\n\nRead and Vote! This insight is:\n1. \ud83d\udc02Positive: https://quantisnow.com/insight/206577?v=0\n2. \ud83d\udc7dNeutral: https://quantisnow.com/insight/206577?v=1\n3. \ud83d\udc3bNegative: https://quantisnow.com/insight/206577?v=2\n\n#majorpharmaceuticals #healthcare",
      "created_at": "2020-12-09T14:01:14Z",
      "user": {
        "id": 4280914,
        "username": "Quantisnow",
        "name": "Quantisnow",
        "avatar_url": "https://avatars.stocktwits.com/production/4280914/thumb-1604765185.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/4280914/thumb-1604765185.png",
        "join_date": "2020-11-07",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 92,
        "following": 1,
        "ideas": 7583,
        "watchlist_stocks_count": 0,
        "like_count": 10,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 5981,
        "title": "Quantisnow",
        "url": "https://quantisnow.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7407
        }
      ],
      "links": [
        {
          "title": null,
          "url": "https://quantisnow.com/insight/206577?v=0",
          "shortened_url": "https://quantisnow.com/insight/206577?v=0",
          "shortened_expanded_url": "quantisnow.com/insight/2065...",
          "description": null,
          "image": null,
          "created_at": "2020-12-09T14:01:15Z",
          "video_url": null,
          "source": {
            "name": "Quantisnow",
            "website": "https://quantisnow.com"
          }
        },
        {
          "title": null,
          "url": "https://quantisnow.com/insight/206577?v=1",
          "shortened_url": "https://quantisnow.com/insight/206577?v=1",
          "shortened_expanded_url": "quantisnow.com/insight/2065...",
          "description": null,
          "image": null,
          "created_at": "2020-12-09T14:01:15Z",
          "video_url": null,
          "source": {
            "name": "Quantisnow",
            "website": "http://quantisnow.com"
          }
        },
        {
          "title": null,
          "url": "https://quantisnow.com/insight/206577?v=2",
          "shortened_url": "https://quantisnow.com/insight/206577?v=2",
          "shortened_expanded_url": "quantisnow.com/insight/2065...",
          "description": null,
          "image": null,
          "created_at": "2020-12-09T14:01:15Z",
          "video_url": null,
          "source": {
            "name": "Quantisnow",
            "website": "https://quantisnow.com"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262707796,
      "body": "$LLY Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio\u00ae \n\nhttps://newsfilter.io/a/7f3ab835e04eddaa8ec02763359c77bc",
      "created_at": "2020-12-09T14:00:59Z",
      "user": {
        "id": 2762379,
        "username": "Newsfilter",
        "name": "@newsfilterio",
        "avatar_url": "https://avatars.stocktwits.com/production/2762379/thumb-1570180226.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/2762379/thumb-1570180226.png",
        "join_date": "2019-09-01",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 8090,
        "following": 16,
        "ideas": 666071,
        "watchlist_stocks_count": 1,
        "like_count": 531,
        "plus_tier": "month",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2269,
        "title": "StockTwits Web",
        "url": "https://stocktwits.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7407
        }
      ],
      "links": [
        {
          "title": "Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio\u00ae",
          "url": "https://newsfilter.io/a/7f3ab835e04eddaa8ec02763359c77bc",
          "shortened_url": "https://newsfilter.io/a/7f3ab835e04eddaa8ec02763359c77bc",
          "shortened_expanded_url": "newsfilter.io/a/7f3ab835e04...",
          "description": "INDIANAPOLIS, Dec. 9, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced additional data from a pre-planned primary outcome analysis from the Phase 3 monarchE trial that showed Verzenio \u00ae (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) decreased the risk of breast cancer recurrence by 28.7 percent compared to standard adjuvant ET alone for people with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (HR: 0.713; 95% CI: 0.583, 0.871; p = 0.0009).",
          "image": null,
          "created_at": "2020-12-09T14:01:00Z",
          "video_url": null,
          "source": {
            "name": "Newsfilter",
            "website": "https://newsfilter.io"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262707745,
      "body": "$LLY Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio\u00ae\nhttps://www.stocktitan.net/news/LLY/lilly-presents-positive-primary-outcome-data-from-monarch-e-that-vk113zxvpjjw.html",
      "created_at": "2020-12-09T14:00:54Z",
      "user": {
        "id": 3372441,
        "username": "Stock_Titan",
        "name": "StockTitan",
        "avatar_url": "https://avatars.stocktwits.com/production/3372441/thumb-1588173612.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/3372441/thumb-1588173612.png",
        "join_date": "2020-04-28",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 593,
        "following": 0,
        "ideas": 41863,
        "watchlist_stocks_count": 0,
        "like_count": 0,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 5677,
        "title": "StockTitan",
        "url": "https://stocktitan.net"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7407
        }
      ],
      "links": [
        {
          "title": "Lilly Presents Positive Primary Outcome Data from monarchE that | StockTitan.net",
          "url": "https://www.stocktitan.net/news/LLY/lilly-presents-positive-primary-outcome-data-from-monarch-e-that-vk113zxvpjjw.html",
          "shortened_url": "https://www.stocktitan.net/news/LLY/lilly-presents-positive-primary-outcome-data-from-monarch-e-that-vk113zxvpjjw.html",
          "shortened_expanded_url": "stocktitan.net/news/LLY/lil...",
          "description": "INDIANAPOLIS, Dec. 9, 2020 -- Eli Lilly and Company (NYSE: LLY) today announced additional data from a pre-planned primary outcome analysis from the Phase 3 monarchE trial that showed Verzenio(R) (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) decreased the risk of breast cancer recurrence by 28.7 percent compared to standard adjuvant ET alone for people with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (HR: 0.713; 95% CI: 0.583, 0.871; p = 0.0009).",
          "image": "https://static.stocktitan.net/company-logo/lly.png",
          "created_at": "2020-12-09T14:00:56Z",
          "video_url": null,
          "source": {
            "name": "Stocktitan",
            "website": "https://www.stocktitan.net"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262702885,
      "body": "$LLY tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20201209064546LLY",
      "created_at": "2020-12-09T13:46:48Z",
      "user": {
        "id": 8115,
        "username": "briefingcom",
        "name": "Briefingcom",
        "avatar_url": "https://avatars.stocktwits.com/production/8115/thumb-1340802633.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/8115/thumb-1340802633.png",
        "join_date": "2010-01-25",
        "official": true,
        "identity": "Official",
        "classification": [
          "official"
        ],
        "followers": 85731,
        "following": 821,
        "ideas": 83032,
        "watchlist_stocks_count": 8,
        "like_count": 68,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2269,
        "title": "StockTwits Web",
        "url": "https://stocktwits.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7407
        }
      ],
      "links": [
        {
          "title": "Briefing.com",
          "url": "https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20201209064546LLY",
          "shortened_url": "https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20201209064546LLY",
          "shortened_expanded_url": "briefing.com/in-depth-analy...",
          "description": null,
          "image": null,
          "created_at": "2020-12-09T13:46:48Z",
          "video_url": null,
          "source": {
            "name": "Briefing",
            "website": "https://www.briefing.com"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262698186,
      "body": "Stocks to watch - Bullish reversals \n$T $JNJ $V $NGL $LLY  \n \nRecovering from recent lows. \nstockbeep.com/wlbur-dec9",
      "created_at": "2020-12-09T13:31:37Z",
      "user": {
        "id": 1572122,
        "username": "Stockbeep_Scanner",
        "name": "stockbeep.com",
        "avatar_url": "https://avatars.stocktwits.com/production/1572122/thumb-1543837039.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/1572122/thumb-1543837039.png",
        "join_date": "2018-08-10",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 4615,
        "following": 11,
        "ideas": 8451,
        "watchlist_stocks_count": 0,
        "like_count": 43,
        "plus_tier": "month",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 1022,
        "title": "Zapier",
        "url": "https://zapier.com/"
      },
      "symbols": [
        {
          "id": 6011,
          "symbol": "JNJ",
          "title": "Johnson & Johnson",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 34074
        },
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7404
        },
        {
          "id": 7341,
          "symbol": "T",
          "title": "AT&T, Inc.",
          "aliases": [
            "ATT"
          ],
          "is_following": false,
          "watchlist_count": 73542
        },
        {
          "id": 7610,
          "symbol": "V",
          "title": "Visa, Inc.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 62754
        },
        {
          "id": 9631,
          "symbol": "NGL",
          "title": "NGL Energy Partners LP",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 1831
        }
      ],
      "links": [
        {
          "title": "Trending Stocks - Recent Price Momentum",
          "url": "stockbeep.com/wlbur-dec9",
          "shortened_url": "stockbeep.com/wlbur-dec9",
          "shortened_expanded_url": "stockbeep.com/trending-stocks",
          "description": "This scan helps traders identify today's trending stocks. A trending stock has an overall upward direction. This is characterized by an upwards price channel. Stockbeep uses a lookback period of 5 days, inclusive of today. The scanner detects stocks with higher highs/lows/closing prices.",
          "image": "https://stockbeep.com/images/twitter/us/trending-stocks-NYSE-NASDAQ-AMEX.png",
          "created_at": "2020-12-09T13:31:37Z",
          "video_url": null,
          "source": {
            "name": "StockBeep",
            "website": "https://stockbeep.com"
          }
        }
      ],
      "likes": {
        "total": 1,
        "user_ids": [
          1955427
        ]
      },
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262685573,
      "body": "$LLY\nEli Lilly (NYSE:LLY) announces top-line results from SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety of tirzepatide compared to placebo in adults with type 2 diabetes.Treatment differences for two estimands \u2013 efficacy and treatment-regimen \u2013 were evaluated for the three tirzepatide doses (5 mg, 10 mg and 15 mg) compared to placebo.Using the efficacy estimand, the highest dose of tirzepatide led to an A1C reduction of 2.07% and reduced body weight by 9.5 kg (11.0%).51.7% of participants in this arm achieved an A1C less than 5.7% \u2013 the level seen in non-diabetic people, 87.9% of partticipants achieved A1C &lt;7%.\nhttps://seekingalpha.com/news/3642823-lillys-tirzepatide-shows-impressive-a1c-and-weight-reductions-for-people-type-2-diabetes\n\nView the full list of news/momentum plays on watch at : bit.ly/32GfaRt\n[No bias / position]\n[Find me at https://stocktwits.com/sbiswas | https://twitter.com/soumyajyoti_b]&quot;",
      "created_at": "2020-12-09T12:45:11Z",
      "user": {
        "id": 1665157,
        "username": "sbiswas",
        "name": "Soumyajyoti Biswas",
        "avatar_url": "https://avatars.stocktwits.com/production/1665157/thumb-1598680399.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/1665157/thumb-1598680399.png",
        "join_date": "2018-10-17",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 357,
        "following": 58,
        "ideas": 4661,
        "watchlist_stocks_count": 22,
        "like_count": 74,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2269,
        "title": "StockTwits Web",
        "url": "https://stocktwits.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7404
        }
      ],
      "links": [
        {
          "title": "Lilly's tirzepatide shows impressive A1C and weight reductions for people with type 2 diabetes (NYSE:LLY)",
          "url": "https://seekingalpha.com/news/3642823-lillys-tirzepatide-shows-impressive-a1c-and-weight-reductions-for-people-type-2-diabetes",
          "shortened_url": "https://seekingalpha.com/news/3642823-lillys-tirzepatide-shows-impressive-a1c-and-weight-reductions-for-people-type-2-diabetes",
          "shortened_expanded_url": "seekingalpha.com/news/36428...",
          "description": "Eli Lilly (NYSE:LLY) announces top-line results from SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety of tirzepatide compared to placebo in adults with type 2 diabetes.Treatment differences for two estimands - efficacy and treatment-regimen - were evaluated for the three tirzepatide doses (5 mg, 10 mg and 15 mg)",
          "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png",
          "created_at": "2020-12-09T12:45:11Z",
          "video_url": null,
          "source": {
            "name": "SeekingAlpha",
            "website": "https://seekingalpha.com"
          }
        },
        {
          "title": "Daily_Trade_Levels - Google Drive",
          "url": "bit.ly/32GfaRt",
          "shortened_url": "bit.ly/32GfaRt",
          "shortened_expanded_url": "docs.google.com/spreadsheet...",
          "description": null,
          "image": null,
          "created_at": "2020-12-09T12:45:11Z",
          "video_url": null,
          "source": {
            "name": "Google",
            "website": "https://docs.google.com"
          }
        },
        {
          "title": "Soumyajyoti Biswas (@sbiswas) | Stocktwits",
          "url": "https://stocktwits.com/sbiswas",
          "shortened_url": "https://stocktwits.com/sbiswas",
          "shortened_expanded_url": "stocktwits.com/sbiswas",
          "description": "The latest messages and market ideas from Soumyajyoti Biswas (@sbiswas) on Stocktwits. I trade only options based on momentum and/or news. I read news pre-market / search for stocks with momentum, and form a daily watch list to trade. Knowledge should always be free.",
          "image": "https://avatars.stocktwits.com/production/1665157/large-1598680399.png",
          "created_at": "2020-12-09T12:45:11Z",
          "video_url": null,
          "source": {
            "name": "Stocktwits",
            "website": "https://stocktwits.com"
          }
        },
        {
          "title": null,
          "url": "https://twitter.com/soumyajyoti_b",
          "shortened_url": "https://twitter.com/soumyajyoti_b",
          "shortened_expanded_url": "twitter.com/soumyajyoti_b",
          "description": null,
          "image": null,
          "created_at": "2020-12-09T12:45:11Z",
          "video_url": null,
          "source": {
            "name": "Twitter",
            "website": "https://twitter.com"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262684047,
      "body": "$LLY Lilly&#39;s tirzepatide shows impressive A1C and weight reductions for people with type 2 diabetes \n\nhttps://newsfilter.io/a/ecfc792a67491bac54583f4191083493",
      "created_at": "2020-12-09T12:37:51Z",
      "user": {
        "id": 2762379,
        "username": "Newsfilter",
        "name": "@newsfilterio",
        "avatar_url": "https://avatars.stocktwits.com/production/2762379/thumb-1570180226.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/2762379/thumb-1570180226.png",
        "join_date": "2019-09-01",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 8085,
        "following": 16,
        "ideas": 665704,
        "watchlist_stocks_count": 1,
        "like_count": 531,
        "plus_tier": "month",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2269,
        "title": "StockTwits Web",
        "url": "https://stocktwits.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7404
        }
      ],
      "links": [
        {
          "title": "Lilly's tirzepatide shows impressive A1C and weight reductions for people with type 2 diabetes",
          "url": "https://newsfilter.io/a/ecfc792a67491bac54583f4191083493",
          "shortened_url": "https://newsfilter.io/a/ecfc792a67491bac54583f4191083493",
          "shortened_expanded_url": "newsfilter.io/a/ecfc792a674...",
          "description": "Lilly's tirzepatide shows impressive A1C and weight reductions for people with type 2 diabetes: Eli Lilly announces top-line results from SURPASS-1 monotherapy clinical trial evaluating the efficacy a..",
          "image": null,
          "created_at": "2020-12-09T12:37:52Z",
          "video_url": null,
          "source": {
            "name": "Newsfilter",
            "website": "https://newsfilter.io"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262677948,
      "body": "$LLY NEW ARTICLE : Lilly&#39;s tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes https://www.stck.pro/news/LLY/9528356",
      "created_at": "2020-12-09T12:05:13Z",
      "user": {
        "id": 1555408,
        "username": "STCKPRO",
        "name": "STCK.PRO",
        "avatar_url": "https://avatars.stocktwits.com/production/1555408/thumb-1576077822.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/1555408/thumb-1576077822.png",
        "join_date": "2018-07-24",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 4863,
        "following": 2,
        "ideas": 298375,
        "watchlist_stocks_count": 18,
        "like_count": 52,
        "plus_tier": "month",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 5011,
        "title": "STCK.PRO",
        "url": "https://dashboard.stck.pro"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7404
        }
      ],
      "links": [
        {
          "title": "ELI LILLY AND COMPANY (LLY) News - STCK.PRO",
          "url": "https://www.stck.pro/news/LLY/9528356",
          "shortened_url": "https://www.stck.pro/news/LLY/9528356",
          "shortened_expanded_url": "stck.pro/news/LLY",
          "description": "Never miss an important article again, stay on top of your investments and become a better investor today! Get your moat on and sync your watchlist with Stocktwits and get all the latest news for your symbols. Sync with Stocktwits",
          "image": "https://www.stck.pro/img/noog.png",
          "created_at": "2020-12-09T12:05:15Z",
          "video_url": null,
          "source": {
            "name": "STCK.PRO",
            "website": "https://www.stck.pro"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "chart": {
          "thumb": "https://charts.stocktwits.com/production/small_262677948.jpg",
          "large": "https://charts.stocktwits.com/production/large_262677948.jpg",
          "original": "https://charts.stocktwits.com/production/original_262677948.jpg",
          "url": "https://charts.stocktwits.com/production/original_262677948.jpg"
        },
        "sentiment": null
      }
    },
    {
      "id": 262677781,
      "body": "$LLY: Lilly&#39;s tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes https://www.chartmill.com/stock/quote/LLY/news?utm_source=stocktwits&amp;utm_medium=pressRelease&amp;utm_content=LLY&amp;utm_campaign=social_tracking",
      "created_at": "2020-12-09T12:04:04Z",
      "user": {
        "id": 47688,
        "username": "ChartMill",
        "name": "ChartMill",
        "avatar_url": "https://avatars.stocktwits.com/production/47688/thumb-1363343728.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/47688/thumb-1363343728.png",
        "join_date": "2011-01-26",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 22994,
        "following": 891,
        "ideas": 1137878,
        "watchlist_stocks_count": 20,
        "like_count": 32,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 1135,
        "title": "ChartMill",
        "url": "http://www.chartmill.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7404
        }
      ],
      "links": [
        {
          "title": null,
          "url": "https://www.chartmill.com/stock/quote/LLY/news?utm_source=stocktwits&utm_medium=pressRelease&utm_content=LLY&utm_campaign=social_tracking",
          "shortened_url": "https://www.chartmill.com/stock/quote/LLY/news?utm_source=stocktwits&utm_medium=pressRelease&utm_content=LLY&utm_campaign=social_tracking",
          "shortened_expanded_url": "chartmill.com/stock/quote/L...",
          "description": null,
          "image": null,
          "created_at": "2020-12-09T12:04:04Z",
          "video_url": null,
          "source": {
            "name": "Chartmill",
            "website": "https://www.chartmill.com"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262676070,
      "body": "$LLY Lilly&#39;s tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes https://www.otcdynamics.com/lly-lillys-tirzepatide-significantly-reduced-a1c-and-body-weight-in-people-with-type-2-diabetes",
      "created_at": "2020-12-09T11:53:04Z",
      "user": {
        "id": 253206,
        "username": "otcdynamics",
        "name": "otcdynamics",
        "avatar_url": "https://avatars.stocktwits.com/production/253206/thumb-1432182723.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/253206/thumb-1432182723.png",
        "join_date": "2013-08-16",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 457,
        "following": 0,
        "ideas": 69181,
        "watchlist_stocks_count": 0,
        "like_count": 56,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 5512,
        "title": "project_n",
        "url": "https://www.otcdynamics.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7404
        }
      ],
      "links": [
        {
          "title": "$LLY Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes",
          "url": "https://www.otcdynamics.com/lly-lillys-tirzepatide-significantly-reduced-a1c-and-body-weight-in-people-with-type-2-diabetes",
          "shortened_url": "https://www.otcdynamics.com/lly-lillys-tirzepatide-significantly-reduced-a1c-and-body-weight-in-people-with-type-2-diabetes",
          "shortened_expanded_url": "otcdynamics.com/lly-lillys-...",
          "description": "INDIANAPOLIS, Dec. 9, 2020 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes after 40 weeks of treatment in topline results from Eli Lilly and Company's (NYSE: LLY) SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety of tirzepatide compared to placebo.",
          "image": null,
          "created_at": "2020-12-09T11:53:06Z",
          "video_url": null,
          "source": {
            "name": "Otcdynamics",
            "website": "https://www.otcdynamics.com"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262676036,
      "body": "$LLY [15s. delayed]: Issued Press Release on December 09, 06:45:00: Lilly&#39;s tirzepatide significantly reduced A1C and body weight in peopl https://s.flashalert.me/8oGvu",
      "created_at": "2020-12-09T11:52:49Z",
      "user": {
        "id": 595702,
        "username": "fla",
        "name": "FlashAlert_me",
        "avatar_url": "https://avatars.stocktwits.com/production/595702/thumb-1550769466.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/595702/thumb-1550769466.png",
        "join_date": "2015-09-09",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 2842,
        "following": 60,
        "ideas": 774537,
        "watchlist_stocks_count": 0,
        "like_count": 4,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 4622,
        "title": "FlashAlert",
        "url": "https://flashalert.me/"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7404
        }
      ],
      "links": [
        {
          "title": "Flash Alert",
          "url": "https://s.flashalert.me/8oGvu",
          "shortened_url": "https://s.flashalert.me/8oGvu",
          "shortened_expanded_url": "prnewswire.com:443/news-rel...",
          "description": "Real-time alerts about equities, ETFs, cryptocurrencies and more sent to any device",
          "image": null,
          "created_at": "2020-12-09T11:52:49Z",
          "video_url": null,
          "source": {
            "name": "Flashalert",
            "website": "https://flashalert.me"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262675287,
      "body": "$LLY | Eli Lilly: Reports Phase 3 Tirzepatide Data In Type 2 Diabetes\n-Cuts AIC 2.07% At Highest Dose",
      "created_at": "2020-12-09T11:46:59Z",
      "user": {
        "id": 130351,
        "username": "LiveSquawk",
        "name": "Live Squawk",
        "avatar_url": "https://avatars.stocktwits.com/production/130351/thumb-1572019929.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/130351/thumb-1572019929.png",
        "join_date": "2012-01-18",
        "official": true,
        "identity": "Official",
        "classification": [
          "suggested",
          "official"
        ],
        "followers": 229451,
        "following": 90,
        "ideas": 146746,
        "watchlist_stocks_count": 22,
        "like_count": 13,
        "plus_tier": "month",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2269,
        "title": "StockTwits Web",
        "url": "https://stocktwits.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7404
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262675159,
      "body": "$LLY ($149.3) Lilly&#39;s tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes https://marketbit.pro/r/ur4PXE1d",
      "created_at": "2020-12-09T11:45:53Z",
      "user": {
        "id": 1442579,
        "username": "StockMeinfo",
        "name": "StockMe.info",
        "avatar_url": "https://avatars.stocktwits.com/production/1442579/thumb-1605608355.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/1442579/thumb-1605608355.png",
        "join_date": "2018-03-13",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 155,
        "following": 6,
        "ideas": 4585,
        "watchlist_stocks_count": 13,
        "like_count": 2,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 2269,
        "title": "StockTwits Web",
        "url": "https://stocktwits.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7404
        }
      ],
      "links": [
        {
          "title": "Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes",
          "url": "https://marketbit.pro/r/ur4PXE1d",
          "shortened_url": "https://marketbit.pro/r/ur4PXE1d",
          "shortened_expanded_url": "marketbit.pro/news/2020/12/...",
          "description": "INDIANAPOLIS, Dec. 9, 2020 INDIANAPOLIS, Dec. 9, 2020 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes after 40 weeks of treatment in topline results from Eli Lilly and Company's (NYSE: LLY) SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety of tirzepatide compared to placebo.",
          "image": "https://www.marketbit.pro/gfx/mbSquareMeta.jpeg?img=true",
          "created_at": "2020-12-09T11:45:55Z",
          "video_url": null,
          "source": {
            "name": "Marketbit",
            "website": "https://www.marketbit.pro"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262675109,
      "body": "$LLY Lilly&#39;s tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes\n\nRead and Vote! This insight is:\n1. \ud83d\udc02Positive: https://quantisnow.com/insight/205806?v=0\n2. \ud83d\udc7dNeutral: https://quantisnow.com/insight/205806?v=1\n3. \ud83d\udc3bNegative: https://quantisnow.com/insight/205806?v=2\n\n#majorpharmaceuticals #healthcare",
      "created_at": "2020-12-09T11:45:35Z",
      "user": {
        "id": 4280914,
        "username": "Quantisnow",
        "name": "Quantisnow",
        "avatar_url": "https://avatars.stocktwits.com/production/4280914/thumb-1604765185.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/4280914/thumb-1604765185.png",
        "join_date": "2020-11-07",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 89,
        "following": 1,
        "ideas": 7447,
        "watchlist_stocks_count": 0,
        "like_count": 10,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 5981,
        "title": "Quantisnow",
        "url": "https://quantisnow.com"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7404
        }
      ],
      "links": [
        {
          "title": null,
          "url": "https://quantisnow.com/insight/205806?v=0",
          "shortened_url": "https://quantisnow.com/insight/205806?v=0",
          "shortened_expanded_url": "quantisnow.com/insight/2058...",
          "description": null,
          "image": null,
          "created_at": "2020-12-09T11:45:36Z",
          "video_url": null,
          "source": {
            "name": "Quantisnow",
            "website": "https://quantisnow.com"
          }
        },
        {
          "title": null,
          "url": "https://quantisnow.com/insight/205806?v=1",
          "shortened_url": "https://quantisnow.com/insight/205806?v=1",
          "shortened_expanded_url": "quantisnow.com/insight/2058...",
          "description": null,
          "image": null,
          "created_at": "2020-12-09T11:45:36Z",
          "video_url": null,
          "source": {
            "name": "Quantisnow",
            "website": "https://quantisnow.com"
          }
        },
        {
          "title": null,
          "url": "https://quantisnow.com/insight/205806?v=2",
          "shortened_url": "https://quantisnow.com/insight/205806?v=2",
          "shortened_expanded_url": "quantisnow.com/insight/2058...",
          "description": null,
          "image": null,
          "created_at": "2020-12-09T11:45:36Z",
          "video_url": null,
          "source": {
            "name": "Quantisnow",
            "website": "https://quantisnow.com"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    },
    {
      "id": 262675101,
      "body": "$LLY Lilly&#39;s tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes\nhttps://www.stocktitan.net/news/LLY/lilly-s-tirzepatide-significantly-reduced-a1c-and-body-weight-in-975e6l1hf7do.html",
      "created_at": "2020-12-09T11:45:35Z",
      "user": {
        "id": 3372441,
        "username": "Stock_Titan",
        "name": "StockTitan",
        "avatar_url": "https://avatars.stocktwits.com/production/3372441/thumb-1588173612.png",
        "avatar_url_ssl": "https://avatars.stocktwits.com/production/3372441/thumb-1588173612.png",
        "join_date": "2020-04-28",
        "official": false,
        "identity": "User",
        "classification": [],
        "followers": 590,
        "following": 0,
        "ideas": 41740,
        "watchlist_stocks_count": 0,
        "like_count": 0,
        "plus_tier": "",
        "premium_room": "",
        "trade_app": false
      },
      "source": {
        "id": 5677,
        "title": "StockTitan",
        "url": "https://stocktitan.net"
      },
      "symbols": [
        {
          "id": 6183,
          "symbol": "LLY",
          "title": "Eli Lilly & Co.",
          "aliases": [],
          "is_following": false,
          "watchlist_count": 7404
        }
      ],
      "links": [
        {
          "title": "Lilly's tirzepatide significantly reduced A1C and body weight in | StockTitan.net",
          "url": "https://www.stocktitan.net/news/LLY/lilly-s-tirzepatide-significantly-reduced-a1c-and-body-weight-in-975e6l1hf7do.html",
          "shortened_url": "https://www.stocktitan.net/news/LLY/lilly-s-tirzepatide-significantly-reduced-a1c-and-body-weight-in-975e6l1hf7do.html",
          "shortened_expanded_url": "stocktitan.net/news/LLY/lil...",
          "description": "INDIANAPOLIS, Dec. 9, 2020 -- Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes after 40 weeks of treatment in topline results from Eli Lilly and Company's (NYSE: LLY) SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety of tirzepatide compared to placebo.",
          "image": "https://static.stocktitan.net/company-logo/lly.png",
          "created_at": "2020-12-09T11:45:36Z",
          "video_url": null,
          "source": {
            "name": "Stocktitan",
            "website": "https://www.stocktitan.net"
          }
        }
      ],
      "mentioned_users": [],
      "entities": {
        "sentiment": null
      }
    }
  ]
}